PYC THERAPEUTICS LIMITED

0.39%

$1.29

Market Cap $1.263B

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

ASX:PAR

CEO Paul Rennie on IPPS Blockbuster Potential and 50% Phase 3 Milestone

Latest Threads

Tag

Subject

PYC

A new charting thread

18:43

7.5K

18:43

Last post drays

7.5K

PYC

Kidney Cyst drug would be a US$10 billion p.a. blockbuster

16:28

9.5K

16:28

Last post unitfree2

9.5K

PYC

ASX 300 index

19/04/26

1.7K

19/04/26

Last post Ladytradr

1.7K

PYC

Quote of the day …

19/04/26

190

19/04/26

Last post Ladytradr

190

PYC

Evans & Partners research

17/04/26

9.0K

17/04/26

Last post TheAnalyst007

9.0K

PYC

Grange competition for June 30 2026 closing PYC price

15/04/26

19K

15/04/26

Last post drays

19K

PYC

Ann: ADOA Program - SRC Approve Progression to Multi-Dose Study

15/04/26

621

15/04/26

Last post

ASX News

621

PYC

Cannacord researchers update

15/04/26

449

15/04/26

Last post drays

449

See All Discussions

Timeline

ADOA Program - SRC Approve Progression to Multi-Dose Study
15 Apr 10:53	Share

Change in substantial holding
01 Apr 20:25	Share

Change of Director's Interest Notice RH
27 Mar 13:17	Share

PKD - Presentation at World Congress of Nephrology
27 Mar 09:58	Share

ADOA Program - Presentation at NANOS 2026
24 Mar 09:01	Share

Regulatory Alignment on Registrational Trial Requirements
16 Mar 09:19	Share

Change of Director's Interest Notice RH IC
10 Mar 18:41	Share

Application for quotation of securities - PYC
09 Mar 19:55	Share

Application for quotation of securities - PYC
06 Mar 09:46	Share

Joint Company Secretary Appointment
04 Mar 19:11	Share

Completion of Retail Entitlement Offer
04 Mar 09:29	Share

PKD Clinical Trial - Approval to Escalate Dosing
27 Feb 08:04	Share

Change in substantial holding
25 Feb 09:35	Share

2026 Q1 Investor Update
24 Feb 09:18	Share

Half Yearly Report and Accounts
23 Feb 18:47	Share

Application for quotation of securities - PYC
18 Feb 09:47	Share

Becoming a substantial holder
13 Feb 12:29	Share

Cleansing Notice under Section 708A(5)(e)
12 Feb 11:39	Share

Application for quotation of securities - PYC
11 Feb 11:45	Share

Despatch of Retail Offer Booklet
09 Feb 13:32	Share

Notification to Ineligible Retail Shareholders
09 Feb 09:23	Share

Retail Offer Booklet
09 Feb 09:21	Share

Investor Webinar
05 Feb 12:09	Share

Completion of Placement and Institutional Entitlement Offer
04 Feb 09:39	Share

Proposed issue of securities - PYC
02 Feb 10:05	Share

Notice Under Section708AA(2)(f)
02 Feb 09:40	Share

PYC Capital Raising Presentation
02 Feb 09:40	Share

PYC Raising up to $653m to Deliver Human Efficacy Data
02 Feb 09:40	Share

Trading Halt
02 Feb 09:16	Share

Quarterly Activities/Appendix 4C Cash Flow Report
23 Jan 08:50	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last $1.29		Change 0.005(0.39%)		Mkt cap ! $1.263B

Open	High	Low	Volume
$1.25	$1.32	$1.25	549.9K

Buyers (Bids)

Vol.	Price($)
516	$1.30

Sellers (Offers)

Price($)	Vol.
$1.31	7283

Last trade - 16.12pm 20/04/2026 (20 minute delay)

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED

Latest Threads

DBO - Further High-Grade Critical Minerals Results Extend Target Zones at Star Range, Utah

Timeline

Featured News

Latest Videos

PYC Therapeutics (ASX:PYC) lands FDA clearance for first human trials of RP11 treatment drug

06 Mar 2023 13:04 (AEDT)

Latest Articles

PYC reports Phase II success in treating degenerative blindness condition

PYC Therapeutics (ASX:PYC) has reported its investigational drug candidate, VP-001, has shown success in patients with Retinitis Pigmentosa type 11 (RP11) in Phase 1/2 clinical trials where improvements were reported by patients for up to 18 months after treatment. Listen to the HotCopper podcast...

PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.(Most gains, however, were quickly sold off.)Autosomal Dominant Optic Atrophy (ADOA)...

Scientific conference spotlights PYC's work on blindness disease treatment

PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News